Disease · MONDO_0002525
Comparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 18 of 18
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe vs Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe: serious adverse events | 3 of 272 | 5 of 270 | 542 | NCT00639158 | Trial comparisons |
| Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID: serious adverse events | 17 of 153 | 8 of 149 | 302 | NCT00770653 | Trial comparisons |
| Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID: Intake of Study Medication Greater Than 80% and Less Than 120%. | 136 of 146 | 137 of 142 | 288 | NCT00770653 | Trial comparisons |
| MCI-196 (Active) + Simvastatin (Placebo)/ Comparison Phase vs Simvastatin (Active) + MCI-196 (Placebo)/ Comparion Phase: serious adverse events | 16 of 128 | 12 of 131 | 259 | NCT00858637 | Trial comparisons |
| Pitavastatin 4 mg vs Atorvastatin 40 mg: serious adverse events | 8 of 143 | 5 of 71 | 214 | NCT00344370 | Trial comparisons |
| Pitavastatin 4 mg vs Atorvastatin 40 mg: NCEP LDL-C Target Attainment | 110 of 141 | 55 of 71 | 212 | NCT00344370 | Trial comparisons |
| Atorvastatin 10 mg vs Atorvastatin 80 mg: Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Run-in) | 0 of 59 | 0 of 25 | 84 | NCT01218204 | Trial comparisons |
| Simvastatin vs Placebo: serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT00935259 | Trial comparisons |
| Ezetimibe vs Placebo: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT01849068 | Trial comparisons |
| Pioglitazone Group vs Comparator Group: serious adverse events | 0 of 16 | 0 of 14 | 30 | NCT01156597 | Trial comparisons |
| Fucoxanthin vs Placebo: deaths from any cause | 0 of 14 | 0 of 14 | 28 | NCT03613740 | Trial comparisons |
| Fucoxanthin vs Placebo: serious adverse events | 0 of 14 | 0 of 14 | 28 | NCT03613740 | Trial comparisons |
| Fenofibrate vs No Intervention: deaths from any cause | 0 of 15 | 0 of 8 | 23 | NCT02455336 | Trial comparisons |
| Fenofibrate vs No Intervention: serious adverse events | 0 of 15 | 0 of 8 | 23 | NCT02455336 | Trial comparisons |
| Icosapent Ethyl vs Usual Care: deaths from any cause | 0 of 12 | 0 of 8 | 20 | NCT03885661 | Trial comparisons |
| Icosapent Ethyl vs Usual Care: serious adverse events | 0 of 12 | 0 of 8 | 20 | NCT03885661 | Trial comparisons |
| Atorvastatin 80 mg + GSK1292263 800 mg vs GSK1292263 800 mg: Number of Participants With Abnormal- Clinically Significant Electrocardiogram (ECG) Findings- Part A | 0 of 4 | 0 of 2 | 6 | NCT01218204 | Trial comparisons |
| Atorvastatin 80 mg + GSK1292263 800 mg vs GSK1292263 800 mg: Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part A | 0 of 4 | 0 of 2 | 6 | NCT01218204 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002525/comparisons